Free Trial
→ Elon’s BIGGEST warning yet? (From Brownstone Research) (Ad) Free BYSI Stock Alerts

BeyondSpring (BYSI) News Today

BeyondSpring logo
$2.02 -0.16 (-7.34%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

BYSI Latest News

BeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint Inhibitors - Nasdaq
July 8, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/beyondspring-inc-reports-promising-results-plinabulin-combination-therapy-patients
BeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint Inhibitors
July 7, 2025  |  quiverquant.comQ
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3110902/0/en/beyondspring-publishes-human-clinical-study-in-med-cell-press-showing-plinabulin-driven-dendritic-cell-maturation-and-tumor-response-after-prior-checkpoint-inhibitor-failure.html
BeyondSpring (NASDAQ:BYSI) Stock Price Down 4.1% - Should You Sell?
June 30, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-stock-price-down-41-should-you-sell-2025-06-30/
BeyondSpring (NASDAQ:BYSI) Trading Up 30% - Here's Why
June 9, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-trading-up-30-heres-why-2025-06-09/
BeyondSpring reports promising phase 2 NSCLC study results
June 5, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/beyondspring-reports-promising-phase-2-nsclc-study-results-93CH-4116553
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
June 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/03/3092584/0/en/beyondspring-presents-efficacy-safety-data-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inh.html
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
May 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/beyondspring-announces-poster-presentation-2025-110000521.html
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
May 15, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/beyondspring-nasdaq-bysi-afford-invest-110527895.html
BeyondSpring (NASDAQ:BYSI) Releases Earnings Results
May 14, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-releases-earnings-results-2025-05-12/
BeyondSpring, Inc.: BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65382103-beyondspring-inc-beyondspring-reports-first-quarter-2025-financial-results-and-provides-corporate-update-399.htm
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/12/3079606/0/en/beyondspring-reports-first-quarter-2025-financial-results-and-provides-corporate-update.html
BeyondSpring (NASDAQ:BYSI) Stock Price Passes Below 50 Day Moving Average - Time to Sell?
April 6, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-stock-price-passes-below-50-day-moving-average-time-to-sell-2025-04-05/
BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
March 29, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64948014-beyondspring-inc-beyondspring-reports-2024-year-end-financial-results-and-highlights-key-clinical-strategic-milestones-399.htm
BeyondSpring (NASDAQ:BYSI) Stock Price Down 3.8% - What's Next?
March 27, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-stock-price-down-38-whats-next-2025-03-26/
BeyondSpring reports FY24 EPS (21c) vs. (34c) last year
March 27, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/beyondspring-reports-fy24-eps-21c-vs-34c-last-year-1034522424
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
March 27, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/beyondspring-reports-2024-year-end-financial-results-and-highlights-key-clinical-strategic-milestones-1034520267
BeyondSpring Files 2024 Annual Report on Form 10-K
March 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/27/3050426/0/en/beyondspring-files-2024-annual-report-on-form-10-k.html
BeyondSpring (NASDAQ:BYSI) Shares Up 0.6% - What's Next?
February 20, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-shares-up-06-whats-next-2025-02-19/
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/science/genetics/seed-therapeutics-secures-fda-rare-pediatric-and-orphan-drug-designations-for-st-01156/ar-AA1y30AG
BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly
January 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/beyondspring-to-sell-portion-of-equity-interest-in-seed-for-35-4meli-lilly-1034277709
BeyondSpring sells SEED Therapeutics shares for $35.4M
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/beyondspring-sells-seed-therapeutics-shares-for-354m/ar-AA1xZTXZ
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
January 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/01/28/3016234/0/en/seed-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-lead-oncology-asset-rbm39-degrader-and-enters-strategic-transactions-with-new-investors.html
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
January 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/01/28/3016236/0/en/beyondspring-announces-35-4-million-sale-of-a-portion-of-equity-interest-in-seed-therapeutics-to-advance-lead-asset-plinabulin-to-anti-cancer-registrational-studies.html
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4% - Here's Why
January 24, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-shares-down-14-heres-why-2025-01-24/
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher - Here's Why
November 27, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/beyondspring-nasdaqbysi-trading-45-higher-heres-why-2024-11-27/
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
November 12, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/beyondspring-presents-efficacy-results-from-phase-2-iit-study-of-plinabulin-1033993346
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
November 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/11/2978241/0/en/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-prior.html
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume
October 2, 2024  |  gurufocus.comhttps://www.gurufocus.com/news/2540838/bysi-sees-quick-539-surge-amid-low-trading-volume
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
September 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/09/16/2946483/0/en/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-.html
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
September 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/09/16/2946478/0/en/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-type-nsclc-at-esmo-congress-2024.html
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3%
September 11, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-percent-advance-2024-09-11/
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
September 3, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/09/03/2939501/0/en/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-pl.html
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5%
August 21, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-percent-decline-2024-08-21/
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
August 6, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/08/06/2924891/0/en/seed-therapeutics-seed-enters-into-strategic-research-collaboration-with-eisai-co-ltd-to-discover-and-develop-novel-molecular-glue-degraders-for-neurodegeneration-and-oncology-indi.html
BeyondSpring (NASDAQ:BYSI) Trading Up 3.1%
July 12, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-percent-advance-2024-07-12/
BeyondSpring (NASDAQ:BYSI) Shares Down 8.8%
June 20, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-percent-decline-2024-06-20/
4,958,143 Shares in BeyondSpring Inc. (NASDAQ:BYSI) Bought by Decheng Capital LLC
May 30, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-sec-filing-2024-05-30/
BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
May 22, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/beyondspring-nasdaq-bysi-shareholders-earned-135425252.html?.tsrc=rss
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
May 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/16/2883333/0/en/beyondspring-r-d-day-highlights-new-plinabulin-development-strategy-for-cancer-and-updates-for-seed-therapeutics.html
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
May 3, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/03/2875017/0/en/beyondspring-to-host-virtual-r-d-day-to-discuss-new-plinabulin-development-strategy-for-cancer-and-updates-for-seed-therapeutics.html
BeyondSpring GAAP EPS of -$0.54, revenue of $1.75M
April 30, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/beyondspring-gaap-eps-of-054-revenue-of-175m/ar-AA1nUN2y
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
April 29, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/29/2871704/0/en/beyondspring-provides-business-update-and-reports-year-end-2023-financial-results.html
BeyondSpring Files 2023 Annual Report on Form 20-F
April 29, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/29/2871703/0/en/beyondspring-files-2023-annual-report-on-form-20-f.html
BeyondSpring Inc. (NASDAQ:BYSI) Sees Significant Increase in Short Interest
March 30, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-options-data-report-2024-03-30/
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
March 25, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/03/25/2851479/0/en/beyondspring-announces-first-patient-dosed-with-pembrolizumab-plinabulin-plus-etoposide-platinum-in-a-phase-2-investigator-initiated-study-of-first-line-extensive-stage-small-cell-.html
BYSI Oct 2024 7.500 call
March 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/BYSI241018C00007500/chart
4,958,143 Shares in BeyondSpring Inc. (NASDAQ:BYSI) Bought by Decheng Capital Management III Cayman LLC
March 13, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-bysi-sec-filing-2024-03-13/
BYSI Mar 2024 7.500 call
March 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/BYSI240315C00007500/chart
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.04%
March 6, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/u-s-stocks-lower-at-close-of-trade-dow-jones-industrial-average-down-1-04/ar-BB1jocnt
Get BeyondSpring News Delivered to You Automatically

Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

BYSI Media Mentions By Week

BYSI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BYSI
News Sentiment
▼
0.00

0.61
▲
Average
Medical
News Sentiment

BYSI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BYSI Articles
This Week
▼
0

0
▲
BYSI Articles
Average Week

Get BeyondSpring News Delivered to You Automatically

Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:BYSI) was last updated on 7/21/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take ...
Priority Gold | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Turn $1K into $50K with This DeFi Gem
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...
Crypto 101 Media | Sponsored